UA102120C2 - Пероральная форма дозирования бендамустина - Google Patents

Пероральная форма дозирования бендамустина

Info

Publication number
UA102120C2
UA102120C2 UAA201106235A UAA201106235A UA102120C2 UA 102120 C2 UA102120 C2 UA 102120C2 UA A201106235 A UAA201106235 A UA A201106235A UA A201106235 A UAA201106235 A UA A201106235A UA 102120 C2 UA102120 C2 UA 102120C2
Authority
UA
Ukraine
Prior art keywords
bendamustine
pharmaceutically acceptable
dosage forms
oral dosage
polyethoxylated
Prior art date
Application number
UAA201106235A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Джеффри Колледже
Маргарета Ольтофф
Original Assignee
Астеллас Дойчленд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40588059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA102120(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астеллас Дойчленд Гмбх filed Critical Астеллас Дойчленд Гмбх
Publication of UA102120C2 publication Critical patent/UA102120C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UAA201106235A 2008-12-03 2009-12-03 Пероральная форма дозирования бендамустина UA102120C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03
PCT/EP2009/008857 WO2010063493A1 (en) 2008-12-03 2009-12-03 Oral dosage forms of bendamustine

Publications (1)

Publication Number Publication Date
UA102120C2 true UA102120C2 (ru) 2013-06-10

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201106235A UA102120C2 (ru) 2008-12-03 2009-12-03 Пероральная форма дозирования бендамустина

Country Status (25)

Country Link
US (4) US20120003305A1 (cg-RX-API-DMAC7.html)
EP (1) EP2367542B1 (cg-RX-API-DMAC7.html)
JP (1) JP5778037B2 (cg-RX-API-DMAC7.html)
KR (1) KR101688038B1 (cg-RX-API-DMAC7.html)
CN (2) CN105363037B (cg-RX-API-DMAC7.html)
AU (1) AU2009321745B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922806B8 (cg-RX-API-DMAC7.html)
CA (1) CA2745525A1 (cg-RX-API-DMAC7.html)
CO (1) CO6400183A2 (cg-RX-API-DMAC7.html)
CY (1) CY1114977T1 (cg-RX-API-DMAC7.html)
DK (1) DK2367542T3 (cg-RX-API-DMAC7.html)
EA (1) EA020354B1 (cg-RX-API-DMAC7.html)
ES (1) ES2451540T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140204T1 (cg-RX-API-DMAC7.html)
IL (1) IL213270A (cg-RX-API-DMAC7.html)
MX (1) MX2011005643A (cg-RX-API-DMAC7.html)
NZ (1) NZ592970A (cg-RX-API-DMAC7.html)
PL (1) PL2367542T3 (cg-RX-API-DMAC7.html)
PT (1) PT2367542E (cg-RX-API-DMAC7.html)
RS (1) RS53201B (cg-RX-API-DMAC7.html)
SI (1) SI2367542T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201400053B (cg-RX-API-DMAC7.html)
UA (1) UA102120C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010063493A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103791B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2575784T3 (en) * 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
WO2013046223A1 (en) * 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
CN116077644A (zh) * 2011-10-31 2023-05-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
SI2656843T1 (sl) 2012-04-26 2015-06-30 Helmut Schickaneder Estri bendamustina in povezane spojine ter njihova medicinska uporaba
MX2015005805A (es) * 2012-11-12 2016-04-15 Ignyta Inc Derivados de bendamustina y métodos para utilizarlos.
MX362032B (es) 2013-03-12 2019-01-04 Cephalon Inc Formulaciones nanoparticuladas y macroparticuladas.
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
JP6571657B2 (ja) 2013-08-27 2019-09-04 ボウドウリス バシリオス ベンダムスチンの薬学的組成物
SG11202003098WA (en) 2017-10-05 2020-05-28 Tube Pharmaceuticals Gmbh Oral bendamustine formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN101119708B (zh) * 2005-01-14 2014-12-24 赛福伦公司 苯达莫司汀冻干药物组合物
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
SI2367542T1 (sl) 2014-05-30
KR101688038B1 (ko) 2016-12-20
HRP20140204T1 (hr) 2014-04-11
AU2009321745B2 (en) 2016-06-23
US10543196B2 (en) 2020-01-28
RS53201B (sr) 2014-06-30
CO6400183A2 (es) 2012-03-15
PL2367542T3 (pl) 2014-05-30
CN105363037B (zh) 2019-02-05
JP2012510484A (ja) 2012-05-10
EA201190011A1 (ru) 2012-02-28
EA020354B1 (ru) 2014-10-30
NZ592970A (en) 2013-05-31
BRPI0922806A2 (pt) 2015-12-22
MX2011005643A (es) 2011-09-27
DK2367542T3 (da) 2014-03-10
WO2010063493A1 (en) 2010-06-10
US20150335588A1 (en) 2015-11-26
ES2451540T3 (es) 2014-03-27
IL213270A (en) 2017-05-29
US20120003305A1 (en) 2012-01-05
CY1114977T1 (el) 2016-12-14
US20170095452A1 (en) 2017-04-06
CN105363037A (zh) 2016-03-02
CA2745525A1 (en) 2010-06-10
BRPI0922806B1 (pt) 2020-03-03
CN102281871A (zh) 2011-12-14
US20140018334A1 (en) 2014-01-16
KR20110102393A (ko) 2011-09-16
JP5778037B2 (ja) 2015-09-16
SMT201400053B (it) 2014-07-07
AU2009321745A1 (en) 2011-06-23
IL213270A0 (en) 2011-07-31
EP2367542A1 (en) 2011-09-28
PT2367542E (pt) 2014-03-10
BRPI0922806B8 (pt) 2021-05-25
EP2367542B1 (en) 2014-01-01
ZA201103791B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
UA102120C2 (ru) Пероральная форма дозирования бендамустина
TN2016000230A1 (en) Orally disintegrating solid dosage unit containing an estetrol component.
NZ746271A (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
ATE540680T1 (de) Pharmazeutische aripiprazol-zusammensetzungen
EA201190145A1 (ru) Фармацевтические композиции, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
CO6531485A2 (es) Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
WO2007100614A3 (en) STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
WO2010042391A3 (en) Hiv integrase inhibitors
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2012064302A3 (en) Improved montelukast formulations
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид
TR201803451T4 (tr) Olmesartan formülasyonlari.
WO2011135582A3 (en) Pharmaceutical compositions of dronedarone
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
WO2011128914A3 (en) Extended release pharmaceutical compositions of pramipexole
WO2020032883A3 (en) Synergistic effects of a novel ketoprofen formulation including a gastro protective agent
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування